Every EPIX Pharmaceuticals imaging pharmaceutical under development includes two components: one, a targeting entity, and two, an image-enhancing group. In these imaging pharmaceuticals, the targeting entity is tethered to the image-enhancing group. This proprietary technology platform, Target Visual Technology (TVT), allows imaging pharmaceuticals to target and highlight specific tissues and fluids in the body. The process not only localizes the imaging pharmaceutical at the target, it also strengthens the magnetic signal, resulting in clearer, brighter images.
The combined capabilities of targeting and image enhancement promise to advance diagnostic imaging and patient management.
